Biofrontera's Model Shift and Pipeline Promise: A Record Quarter with a Patent Cloud

Strongest H1 as a standalone company, near breakeven, and a tangible line to future growth through sBCC and label expansions.

BFRA · Earnings Call · 2026-08-13

Biofrontera's second-quarter report captured a company at an inflection point—strong financial execution, a resolved business model, and a pipeline that promises further acceleration, all set against an ongoing patent dispute that management insists is manageable.

A Transformative Quarter

The numbers tell the story: “We delivered product revenues of $12 million in the second quarter, an increase of approximately 33% year-over-year.” — George Jones, Unknown · 2026-08-13 That growth came from a 30% increase in Ameluz unit volume plus a price increase implemented in Q4 2025. Gross margin expanded to ~80% from ~71%, a surge driven by the October 2025 strategic transaction that replaced a 25–35% transfer pricing model with a 12% earn-out on net sales. The result was an adjusted EBITDA loss of just $0.2 million versus $5.1 million in the prior-year quarter—essentially breakeven in what is historically a weak quarter. CFO Eugene Leffler framed the durability of the improvement: “Adjusted EBITDA for the quarter was negative $0.2 million compared with negative $5.1 million in the prior year quarter, an improvement of approximately $5 million.” — Eugene Leffler, Unknown · 2026-08-13 This is not a one-off; the cost structure is contractual and the company is now generating cash from operations, a sharp contrast to the $7.2 million burn in H1 2025. The successful execution of the new model is reflected in the commercial readiness of the organization—order counts up 18.6% in H1, with repeat customers ordering more.

The ITC Overhang and Remediation

The overhang is the International Trade Commission (ITC) ruling against the RhodoLED XL lamp, which took effect on July 7. The company can no longer import or sell the current XL, nor sell Ameluz for use with it. Yet management is careful to delineate the scope: “First, this affects the XL lamp. It does not in any way affect the original BF-RhodoLED lamp, which represents the substantial majority of our installed lamp base.” — Hermann Lubbert, Unknown · 2026-08-13 With an installed base of ~801 lamps, only ~243 are XLs, and many XL customers stocked up on Ameluz before the order took effect, mitigating near-term impact. The remediation plan involves a minor modification to the lamp, as CEO Hermann Luebbert explained:

We have to remove that component of the hinge to actually get beyond the space of those patents. So it's really a minor change that we're introducing into the lamps.
Hermann Lubbert, Unknown · 2026-08-13

The company has received FDA permission to sell the modified version through a CBE-30 process, but is awaiting border control clearance. Meanwhile, it retains the right to appeal the ITC decision to the Federal Circuit. As Luebbert said, “our commercial plan does not depend on winning any of them.” — Hermann Lubbert, Unknown · 2026-08-13 This pragmatic approach keeps the approval process moving and preserves the installed-base value.

Pipeline: More Indications, Same Infrastructure

The most compelling growth driver is the pipeline. The sBCC supplemental NDA has a PDUFA date of September 28, 2026, and the company expects a full launch in Q1 2027. If approved, Ameluz would be the first PDT approved for cancerous skin tumors in the U.S. The beauty is that this launch flows through the same sales force and installed lamp base—no new infrastructure required. "The great thing about the sBCC indication is how perfectly it fits within our current call point and our current kind of strategic priorities," said George Jones on a prior call, “There is no additional work or preparation that has to be done. We're actively preparing for the launch of that indication right now...” — George Jones, Chief Commercial Officer · 2026-05-14 The company also plans to file an sNDA for AK on extremities, neck, and trunk by end of Q3 2026, targeting an approval in Q3 2027. And the acne program is advancing toward Phase III. These label expansions are designed to drive revenue through an already-paid-for commercial organization. As management has reiterated, the growth model for 2027 and beyond is more approved uses flowing through existing infrastructure—a key element of the company's future success. With revenue growth, expanding margins, and a clear path to cash flow breakeven, Biofrontera is demonstrating that it can navigate near-term legal challenges while building a franchise around its photodynamic therapy platform.